PBAC's latest decision on Cetuximab: Recommended (2024). Considered for Treatment of metastatic colorectal cancer (mCRC) in RAS wild-type patients, including first-line treatment in combination with chemotherapy, second-line treatment following first-line chemotherapy or pembrolizumab, and BRAF V600E variant mCRC in combination with encorafenib. Also for squamous cell cancer of the larynx, oropharynx or hypopharynx concomitant with radiotherapy.
PBAC outcome
Recommended
Authority Required
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
11
first 2005
Submissions
11
2005 → 2024
Eligible population
Patients with RAS wild-type metastatic colorectal cancer receiving cetuximab as first-line (in combination with chemotherapy) or second-line (following first-line chemotherapy or pembrolizumab) treatment, or BRAF V600E variant mCRC in combination with encorafenib.
Therapy area
Oncology
Line of therapy
First-line | Second-line
Evidence base
Meta-analysis
Primary endpoint
OS | PFS | ORR
Economic model
Cost-minimisation
Budget impact
$4M
ICER note
This is a Category 4 submission for an alternative dosing regimen (500 mg Q2W versus 250 mg Q1W) of an already-listed drug. No economic evaluation or ICER was required; the submission presented cost comparison only.
ICER (historical)
$75k/QALY–$105k/QALY across 6 submissions (2005–2016) — the latest submission carried no numeric base case. No single PSD states this combined range; see source PSDs.
Submission history
Nov 2005: Not recommended — ICER $105k/QALY
Mar 2007: Recommended with restriction · Authority Required — ICER $45k/QALY
Nov 2008: Not recommended · Authority Required — ICER $200k/QALY
Mar 2009: Not recommended · Authority Required — ICER $200k/QALY